Literature DB >> 20847305

Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia.

Andrew N Hoofnagle1, Mingyuan Wu, Albina K Gosmanova, Jessica O Becker, Ellen M Wijsman, John D Brunzell, Steven E Kahn, Robert H Knopp, Timothy J Lyons, Jay W Heinecke.   

Abstract

OBJECTIVE: To determine whether obesity and insulin resistance associate with changes in the protein content of high-density lipoprotein (HDL) in 2 different groups of men by using targeted proteomics. METHODS AND
RESULTS: Insulin resistance and obesity are hallmarks of type 2 diabetes mellitus and the metabolic syndrome, which confer an increased risk of cardiovascular disease. Recent studies suggest that the protein cargo of HDL makes important contributions to the lipoprotein's cardioprotective effects. In a discovery study, we used isotope dilution mass spectrometry to quantify the relative concentrations of 5 proteins previously implicated in HDL's cardioprotective effects in 3 groups of healthy subjects: lean insulin-sensitive, lean insulin-resistant, and obese insulin-resistant individuals. We validated our findings in a different group of subjects. The clusterin concentration in HDL strongly and negatively associated with insulin resistance and body mass index in both populations. HDL clusterin levels were lower in subjects with low HDL and high triglycerides, key components of the metabolic syndrome. There was an inverse correlation between clusterin levels in HDL and very-low-density lipoprotein/low-density lipoprotein.
CONCLUSIONS: Clusterin levels in HDL are lower in men with reduced insulin sensitivity, higher body mass index, and an unfavorable lipid profile. Our observations raise the possibility that clusterin depletion contributes to the loss of HDL's cardioprotective properties.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847305      PMCID: PMC2988100          DOI: 10.1161/ATVBAHA.110.212894

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  44 in total

Review 1.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

2.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  Insulin resistance and atherosclerosis.

Authors:  Babak Razani; Manu V Chakravarthy; Clay F Semenkovich
Journal:  Endocrinol Metab Clin North Am       Date:  2008-09       Impact factor: 4.741

4.  The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments.

Authors:  Miriam Cnop; Melinda J Landchild; Josep Vidal; Peter J Havel; Negar G Knowles; Darcy R Carr; Feng Wang; Rebecca L Hull; Edward J Boyko; Barbara M Retzlaff; Carolyn E Walden; Robert H Knopp; Steven E Kahn
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus.

Authors:  Takeshi Kujiraoka; Hiroaki Hattori; Yoshikazu Miwa; Mitsuaki Ishihara; Takahiro Ueno; Jun Ishii; Masahiro Tsuji; Tadao Iwasaki; Yoshiyuki Sasaguri; Takayuki Fujioka; Satoshi Saito; Motoo Tsushima; Taro Maruyama; Irina P Miller; Norman E Miller; Tohru Egashira
Journal:  J Atheroscler Thromb       Date:  2006-12       Impact factor: 4.928

6.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids.

Authors:  M Navab; S Y Hama; G P Hough; G Subbanagounder; S T Reddy; A M Fogelman
Journal:  J Lipid Res       Date:  2001-08       Impact factor: 5.922

7.  Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1.

Authors:  Yara Banz; Otto M Hess; Simon C Robson; Eva Csizmadia; Daniel Mettler; Pascal Meier; André Haeberli; Sidney Shaw; Richard A Smith; Robert Rieben
Journal:  Cardiovasc Res       Date:  2007-08-02       Impact factor: 10.787

8.  C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice.

Authors:  Erdenechimeg Shagdarsuren; Kiril Bidzhekov; Yassin Djalali-Talab; Elisa A Liehn; Mihail Hristov; Robert A Matthijsen; Wim A Buurman; Alma Zernecke; Christian Weber
Journal:  Circulation       Date:  2007-12-10       Impact factor: 29.690

9.  Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity.

Authors:  Margarethe Schwarz; Lena Spath; Cornelia A Lux; Kerstin Paprotka; Michael Torzewski; Katrin Dersch; Claudia Koch-Brandt; Matthias Husmann; Sucharit Bhakdi
Journal:  Thromb Haemost       Date:  2008-07       Impact factor: 5.249

10.  Influence of C3 deficiency on atherosclerosis.

Authors:  Chiara Buono; Carolyn E Come; Joseph L Witztum; Graham F Maguire; Philip W Connelly; Michael Carroll; Andrew H Lichtman
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

View more
  27 in total

1.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

Review 2.  Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.

Authors:  Amy S Shah; Lirong Tan; Jason Lu Long; W Sean Davidson
Journal:  J Lipid Res       Date:  2013-02-24       Impact factor: 5.922

3.  Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men.

Authors:  Katya B Rubinow; Chongren Tang; Andrew N Hoofnagle; Christin N Snyder; John K Amory; Jay W Heinecke; Stephanie T Page
Journal:  Steroids       Date:  2012-01-15       Impact factor: 2.668

4.  Circulating clusterin (apolipoprotein J) levels do not have any day/night variability and are positively associated with total and LDL cholesterol levels in young healthy individuals.

Authors:  Konstantinos N Aronis; Maria T Vamvini; John P Chamberland; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2011-09-07       Impact factor: 5.958

5.  Simultaneous LC/MS/MS quantification of eight apolipoproteins in normal and hypercholesterolemic mouse plasma.

Authors:  Richard Wagner; Julia Dittrich; Joachim Thiery; Uta Ceglarek; Ralph Burkhardt
Journal:  J Lipid Res       Date:  2019-02-05       Impact factor: 5.922

6.  Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus.

Authors:  Sang Soo Kim; Sang Heon Song; Jong Ho Kim; Yun Kyung Jeon; Bo Hyun Kim; Min-Cheol Kang; Sung Wan Chun; Soo Hyun Hong; Michelle Chung; Yong Ki Kim; In Joo Kim; Young-Bum Kim
Journal:  Clin Endocrinol (Oxf)       Date:  2017-05-22       Impact factor: 3.478

Review 7.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 8.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

Review 9.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

10.  Circulating ApoJ is closely associated with insulin resistance in human subjects.

Authors:  Ji A Seo; Min-Cheol Kang; Theodore P Ciaraldi; Sang Soo Kim; Kyong Soo Park; Charles Choe; Won Min Hwang; Dong Mee Lim; Olivia Farr; Christos Mantzoros; Robert R Henry; Young-Bum Kim
Journal:  Metabolism       Date:  2017-10-03       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.